A stability-indicating high-performance liquid chromatography (HPLC) procedure was developed for the determination of metformin HCl (MTH), atorvastatin calcium (AC) and glimepiride (GP) in combination and their main degradation products. The separation and quantization were achieved on a 5-µm Qualisil gold, C18 column (4.6 mm × 250 mm). The mobile phase selected was phosphate buffer ( pH 2.9)-organic phase in proportion of 70:30. Organic phase consisted of methanol-acetonitrile (90:10) at a flow rate of 1 mL/min and detection of analytes was carried out at 230 nm. The method exhibited good linearity over the range of 10-60 µg/mL for MTH, 2-20 µg/mL for AC and 5-30 µg/mL for GP. Square of the correlation coefficients was found to be >0.999. Various stress degradation studies were carried out in combination as per International Conference of Harmonization (ICH) guidelines for 4 h. The recovery and precision were determined in terms of intraday and interday precisions and expressed as relative standard deviations. These were <1 and <2%, respectively. Finally, the applicability of the method was evaluated in nanoparticle analysis of MTH, AC and GP as well as in stability studies of nanoformulation.
Introduction
International Conference of Harmonization (ICH) has revised parent drug stability testing guidelines Q1A (R2) for stress testing on the drug substance. Tests should be carried out to ascertain its inherent stability and for supporting the suitability of the proposed analytical procedures (1) . It is recommended that stress testing should be studied for its effect on thermal, humidity, photo stability, oxidation as well as hydrolytic degradation. The aim of this study was to develop inherent stability pattern of combination of metformin HCl (MTH), glimepiride (GP) and atorvastatin calcium (AC) as per ICH guidelines (2) and to develop a validated stability-indicating method by reversed phase high-performance liquid chromatography (RP-HPLC).
MTH is a biguanide antidiabetic drug, which is chemically known as 1,1-dimethyl biguanide monohydrochloride ( Figure 1a ). It decreases hepatic glucose production and also intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
AC is a synthetic lipid-lowering agent, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)β-δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[( phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate (Figure 1b) . It acts as an inhibitor to the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis (3) . It is an organic acid with a pK a of 4.46, insoluble in aqueous solutions of pH 4 and below; and sparingly soluble in distilled water and pH 7.4 phosphate buffer.
GP is a medium-to-long acting sulfonyl urea, an antidiabetic drug. There are a few reported liquid chromatography-mass spectrometry (LC-MS) methods which are available for analysis of antidiabetic drugs and its metabolites in human plasma and urine (5-7). Several methods have been developed individually and for combined dosage forms in human plasma for aforementioned drugs (8) (9) (10) . Even though various methods were reported in the literature for estimation of MTH, GP and pioglitazone alone and in combination with other drugs (11) (12) (13) (14) . As per reports till date there is no information available on the stability behavior of these drugs under hydrolytic, oxidative, thermal and photo degradative conditions. To the best of our knowledge, this is the first report of a stability-indicating method for the determination of MTH, AC, GP in combination as well as its degradative products.
Experimental and methods

Materials and reagents
MTH, AC and GP were obtained as a gift sample from Arti drugs Ltd, Mumbai, India; Cadila Pharmaceuticals Ltd, Ahmadabad, India and Cipla Ltd, Mumbai, India, respectively. HPLC grade acetonitrile, methanol, potassium dihydrogen phosphate and ortho-phosphoric acid were purchased from S.D. Fine Chemicals (Mumbai, India). Furthermore, 0.45 µm membranes were purchased from Pall Life Sciences. All other chemicals used were of analytical grade unless otherwise indicated. High purity water using Milli Q Plus purification system (Millipore, Bedford, MA, USA) was used for the preparation of mobile phase.
Instrumentation
The HPLC system consisted of Agilent 1100 modules (G1310A Isocratic Pump with solvent container, G1314A VW Detector with standard flow cell and G1328A Manual Injector). The output signal was monitored and processed using an Agilent single G2220AA 2D-Value Solution ChemStation. Chromatographic separation was achieved on a 5 µm, Qualisil gold, C18 column (4.6 mm × 250 mm) procured from LC-GC Chromatography Solutions Pvt. Ltd, Mumbai, India. This column can also be purchased from Agilent Technologies Inc., USA ( part number: US603-25). The mobile phase employed comprised solvent A: phosphate buffer ( pH 2.9) (70%) and solvent B: organic phase (30%). The organic phase consists of methanol-acetonitrile (90:10). Prior to use, buffer was filtered through a 0.45 µm filter membrane. Mobile phase was pumped through the column at the flow rate of 1.0 mL/min. The injection volume was 20 µL. The analytes were analyzed at a single wavelength of 230 nm for MTH, AC, GP and their associated degradation products.
Preparation of phosphate buffer
Phosphate buffer solution (0.2 M) was prepared by dissolving 27.22 g of monobasic potassium phosphate in 1,000 mL of water, and pH was adjusted to 2.9 with O-phosphoric acid.
Preparation of stock and standard solutions
Stock solution of MTH, AC and GP (100 µg/mL) was prepared by dissolving accurately weighed 10 mg each of MTH, AC and GP in mobile phase using 100 mL volumetric flasks separately. Standard solutions were prepared by dilution of the stock solution with mobile phase to give solutions containing MTH in the concentration range of 10-60 µg/mL, AC in the concentration range of 5-30 µg/mL and GP in the range of 2-20 µg/mL.
Forced degradation studies
Effect of acid and base hydrolysis
Sample solution containing 1 mL aliquot of MTH, AC and GP was transferred into a 10-mL amber volumetric flask, then mixed with 1 mL of 1 M HCl as well as 1 M NaOH separately and left to stand for 4 h at 80 ± 2°C. Both the samples were injected in triplicate after the neutralizing procedure and chromatogram was run as described previously. 
Validation of RP-HPLC Method and Stress DegradationEffect of oxidation
Sample solution containing 1 mL aliquot of MTH, AC and GP was transferred into a 10-mL amber volumetric flask, then mixed with 1 mL of 1% (v/v) hydrogen peroxide and left to stand for 4 h at 80°C ± 2°C. The final solutions were injected in triplicate and chromatogram was run as described previously.
Effect of photo degradation
Photolytic degradation was studied by placing a 20 µg/mL solution of MTH, AC and GP (diluted with mobile phase) in a clear volumetric flask and exposing it to direct sunlight for 4 h. The resultant solution was injected in triplicate, and the chromatogram was run as described previously.
Heat-induced degradation
One milliliter aliquot of a sample solution containing MTH, AC and GP was transferred to a 10-mL amber volumetric flask and then heated for 4 h at 80 ± 2°C. The resultant solution was injected in triplicate, and the chromatogram was run as described previously. 
Method validation
Linearity and range
The working standard solutions of 100 µg/mL were prepared and further diluted with mobile phase so as to obtain a mixture of MTH, AC and GP in the range of 10-60, 5-30 and 2-20 µg/mL, respectively. The calibration curves were drawn by plotting the peak areas of the drug against the corresponding concentration. The slope and Y intercept of the calibration curve were calculated.
Recovery and precision
Recovery and precision determination was carried out at a concentration of 5, 15 and 30 µg/mL for AC, at 10, 30 and 60 µg/mL for MTH and at 2, 8 and 20 µg/mL for GP. At each level of the amount, six determinations were performed and both intra-and interday variation were expressed in terms of % relative standard deviation (% RSD).
Limit of detection and limit of quantification
To estimate the limit of detection (LOD) and limit of Quantification (LOQ), mobile phase was injected six times following the same method as explained above. The LOD and LOQ for all actives were estimated at a signal-to-noise ratio (S/N) of 3:1 and 10:1, respectively.
Ruggedness and robustness test
As recommended in the ICH guidelines, a robustness assessment was performed during the development of the analytical procedure (15) . The ruggedness (16) of the method is assessed by comparison of the intra-and interday precision results for MTH, AC and GP. This was performed on two different instruments by two analysts in the same laboratory. In addition, the robustness of the method was investigated under a variety of conditions including changes of flow rate, analyst, column temperature, composition of buffer and detector wavelength (17) .
Solution stability
The solution stability of all actives was carried out by leaving a spiked sample (20 µg/mL) solution in a tightly capped volumetric flask at room temperature for 12 h. Content of MTH, AC and GP was determined at 1, 2, 4, 6 and 12 h intervals by following the procedure as described previously.
Application of the developed RP-HPLC method for nanoformulation evaluation
Analysis of MTH, AC and GP from polymeric nanoparticles
To determine the content of MTH, AC and GP in spray-dried polymeric nanoparticles (label claim: 10 mg each of MTH, AC and GP per 120 mg of spray-dried polymeric nanoparticles), 60 mg nanoparticles equivalent to 5 mg of MTH, AC and GP were accurately weighed and transferred to a volumetric flask containing 50 mL mobile phase. To ensure complete extraction of the drug, it was further sonicated for 10 min and then volume was made up to 100 mL. The resulting solution was filtered through 0.45 µm membrane and analyzed for drug content. The filtrate containing 15 µg/mL of the drug was injected and the chromatogram was run as previously described. The analysis was repeated in six individual steps and the possibility of excipient interference in the analysis was studied.
Results
The separation and quantification were achieved on a 5 µm, Qualisil gold, C18 column (4.6 mm × 250 mm). Initially, the ratio of buffer-organic phase was optimized by carrying out variations in the proportion of both phases. When only methanol was used as an organic phase, all three peaks were resolved but there was no reproducibility in the peak area. So acetonitrile was introduced in the organic phase, initially in concentration of 5% and then increased up to 10%. The optimized mobile phase was phosphate buffer ( pH 2.9)-organic phase in proportion of 70:30. Organic phase consisted of methanol-acetonitrile (90:10), set at a flow rate of 1 mL/min and detection of analytes was carried out at 230 nm. The flow rate of 1 mL/min was selected for further studies after several preliminary investigatory chromatographic runs. Under the described experimental conditions, well-defined peaks were obtained by fixing the run time of 10 min and all peaks were free from tailing (Figures 2a-c and 3 ).
Forced degradation of MTH, AC and GP
The chromatograms of the samples of MTH, AC and GP subjected to various forced degradation conditions showed well-separated peaks of the actives and the degradation products at different retention times. However, in some conditions the actives did not show separate peaks of the degradation products, rather a decrease in height and area of the peak was observed. The peaks of the degradation products were identified and compared with that of the standard solution and were found to be well resolved from the peaks of the actives (Figures 4a, b, 5a, b  and 6a ).
Acid degradation
The chromatogram for acidic degradation of MTH, AC and GP showed degradation of ∼0.5, 81.55 and 13.06%, respectively (Figure 4a) . The chromatogram of AC presented two additional peaks at 6.4 and 7.2 min, but only a small change in peak area and a decrease in peak height were observed in the case of MTH and GP.
Base degradation
The chromatogram for basic degradation of the actives showed degradation of ∼42.75 ± 0.78%, 2.29 ± 0.88% and 8.52 ± 0.19% for MTH, AC and GP, respectively. The chromatogram of AC exhibited one additional peak at 2.75 min (Figure 4b ).
Oxidative degradation studies
The chromatograms of MTH, AC and GP showed 0.9, 18.57 and 14.15% degradation, respectively, in response to oxidative degradation and one additional peak at 3.96 min (Figure 5a ) for MTH. 
Photo degradation
Photo degradation resulted in degradation of 16.65 ± 0.47%, 18.57 ± 0.97% and 1.2 ± 0.09% for MTH, AC and GP, respectively (Figure 5b) .
Heat degradation MTH, AC and GP were evinced at 16.65 ± 0.47%, 18.57 ± 0.97% and 1.2 ± 0.09%, respectively (Figure 6a ).
Method development
The developed method was validated, as described below, for the following parameters: system suitability, linearity, LOD, LOQ, ruggedness, robustness and recovery-precision.
System suitability
As the system suitability test is an integral part of chromatographic method development and it is used to verify that the system is adequate for the analysis to be performed, the parameters for combination of three APIs were evaluated and results are reported in Table I .
Linearity and range
Linearity of the standard curve was established by least squares linear regression. The developed standard curve was linear over the concentration range of 10-60 µg/mL for MTH (n = 5), 5-30 µg/mL for AC(n = 5) and 2-20 µg/mL for GP (n = 5).
Recovery and precision
The recovery of an analytical method is the closeness of the test results to the true value. It has been determined by application of the analytical procedure to recovery studies, where low medium and high concentrations were analyzed. The results of recovery studies are shown in Table II . The precision of an analytical procedure expresses the degree of scatter between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. The intra-and interday precision results obtained are shown in Table III .
LOQ and LOD
The detection limit and quantification limit were calculated by the method as described previously. The S/N of 3:1 and 10:1 were considered LOD and LOQ, respectively. The LOD for MTH, AC and GP was observed to be 0.73, 1.1 and 0.39 ppm, respectively. Similarly, the LOQ was calculated for MTH, AC and GP and it was observed to be 2.37, 3.33 and 1.17 ppm, respectively.
Ruggedness and robustness test
Ruggedness and robustness study results are shown in Table IV. 
Solution stability
The % of RSD for MTH, GP and AC concentration during solution stability experiments was within 1%. There was no significant change observed for the chromatograms of standard solution and the experimental solution. Further, the absence of degradation peaks confirmed that the sample is stable in solvent used during the assay for 24 h.
Application of the developed RP-HPLC method for nanoformulation evaluation HPLC chromatogram was obtained from nanoparticle sample, excluding the formation of the degradation products. There was no interference from the excipients commonly present in the formulations (Figure 6b ). The percent drug content for MTH, AC and GP was found to be 101.05, 99.94 and 100.78%, respectively, with a % RSD of <1.
Discussion
The development of a stability-indicating assay method for a combination of MTH, AC and GP; since it is a popularly used combination of drugs and moreover there are no reports recounting an analytical method to identify the degradation products that might arise from exposure of this combination of drugs to different environmental conditions. Various mobiles phases and mobile phase compositions were evaluated at the beginning of the development to arrive at an optimized mobile phase composition which yields suitable peaks for all the three drugs with proper resolution. There are some reports which illustrate various mobile-phase compositions for separation of MTH, AC and GP combinations and as an individual entity. Raja et al. has described a method for separation of MTH, pioglitazone and GP where the authors employed mobile phase system comprising of methanol and phosphate buffer ( pH 3) in the ratio of 75:25 (v/v). The composition, pH and flow rate of the mobile phase were altered to optimize the separation conditions using standard samples of the MTH, AC and GP. The final mobile phase composition in the current research comprised phosphate buffer ( pH 2.9)-organic phase (methanol-acetonitrile, 90:10) in the ratio of 70:30 at a flow rate of 1 mL/ min and detection of analytes was carried out at 230 nm. The linearity results were within the acceptable limits (R 2 , correlation coefficient is 0.999). The tailing factor for the peak was <2% with good resolution between the three peaks. Stress testing showed that MTH, AC and GP degraded via acid, base, oxidation, heat and photochemical degradation, with formation of two or one degradation product. This may be caused by intramolecular abridgment of three molecules (18) . Thus, care should be taken in the manufacturing process and during storage of this product in order to prevent degradation, for the reason that drug degradation could attenuate the therapeutic activity and safety. The chromatograms of the samples of the degradation studies showed that the method was able to separate MTH, AC and GP from its degradation products unlike any of the earlier described analytical methods for this combination. The suitability results of the chromatographic system (number of theoretical plates per meter, RT, resolution and symmetry) was demonstrated by comparing the obtained parameter values, which are found to be within the acceptance criteria of the CDER guidance document (19) . The LOD values 0.79, 1.10 and 0.39 µg /mL for MTH, AC and GP, respectively, and the LOQ values 2.37, 3.33 and 1.17 µg /mL, respectively, for MTH, AC and GP, indicated that this method is suitable for application of nanoparticle formulation. The recovery results at all the three concentration levels, i.e. 5, 15, 30 µg/mL for AC, 10, 30, 60 µg/mL for MTH and 2, 8, 20 µg/mL for GP, are within the acceptable limit (recovery ranged from 98 to 100%) at interday and intraday variation, which indicated that the method is highly accurate. The precision study results showed low values of % RSD (<2) for inter and intraday variation, which suggested an excellent precision of the method. The ruggedness and robustness test results are within the acceptable limits (flow rate, analyst, column temperature, composition of buffer and detector wavelength), which indicates that the method is highly robust. As the system suitability test is an integral part of chromatographic method development and it is used to verify that the system is adequate for the analysis to be performed, the parameters for combination of three APIs were evaluated.
The chromatographic system was found to be suitable for the evaluation of the drug content of this combination from the nanoparticle formulation. In the chromatogram of the MTH, AC and GP combination of the samples extracted from nanoparticles, there was no interference from the excipients commonly present in formulation. The low % RSD value indicated the suitability of this method for routine analysis of combination of MTH, AC and GP in pharmaceutical dosage forms as well as nanoparticulate formulations. 
Conclusion
The developed HPLC method is precise, specific, accurate and stability indicating for the determination of MTH, AC and GP in combination.
The results of statistical analysis also proves that the method is reproducible and specific for the analysis of MTH, AC and GP. The method is versatile for analysis of formulations such as nanoparticles of MTH, AC and GP. 
